China Biologic Profile

101.26
USD 0.14  0.14%
50%
55%

Exercise or conversion by Zhijing Liu of 6358 shares of China Biologic subject to Rule 16b-3

China Biologic Products Holdings insider trading alert for exercise of stock option (right to buy) by Zhijing Liu, Corporate Vice President, on July 15, 2018. This event was filed by China Biologic Products H with SEC on 2017-05-10. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

China Biologic Summary

China Biologic Products Holdings (CBPO) is traded on BATS Exchange in USA. It is located in CHINA and employs 1,871 people. China Biologic is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 3.36 B. China Biologic Products Holdings conducts business under Healthcare sector and is part of Pharmaceuticals And Biosciences industry. This company has 33.2 M outstanding shares of which 1.8 M shares are currently shorted by private and institutional investors with about 4.3 trading days to cover. China Biologic Pr currently holds about 366.64 M in cash with 112.49 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.04.
Check China Biologic Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 101.26HorizonTargetOdds Above 101.26
68.86%30 days 101.26 30.92%
Based on normal probability distribution, the odds of China Biologic to move above current price in 30 days from now is about 30.92% (This China Biologic Products Holdings probability density function shows the probability of China Biologic Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
James Hambro PartnersCommon Shares14414 K
Bank Of MontrealCommon Shares11011 K
View China Biologic Diagnostics

Selected China Biologic Products Holdings Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

China Biologic Against Markets

Risk Adjusted
Performance Score (0 to 100)
3 
Chance of
Financial Distress (0 to 100%)
50 
Equity ratings for China Biologic Products Holdings are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the Peoples Republic of China. China Biologic Products Holdings, Inc. is headquartered in Beijing, the Peoples Republic of China. China Biologic operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 1871 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
China Biologic Products SEC Filings
China Biologic SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameChina Biologic Products Holdings
ChairmanDavid GaoView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationCHINA
Business AddressJialong International Tower
Foreign Associate  Mexico
ExchangeBATS Exchange
CIK Number0001369868
ISINUS16938C1062
CUSIPG21515104
SectorHealthcare
IndustryPharmaceuticals And Biosciences
BenchmarkDOW
Websitewww.chinabiologic.com
Phone86 10 6598 3111
CurrencyUSD - US Dollar

China Biologic Corporate Directors

Min Fang Director, MBA
Joseph Chow Independent Director, MBA
Xiaosheng Shao Independent Director
Check also Trending Equities. Please also try Commodity Channel Index module to use commodity channel index to analyze current equity momentum.